Peptides for Disease — Top Peptides ·
This article explores peptides studied or used for epilepsy, highlighting ACTH as an FDA-approved treatment for infantile spasms and Selank, which is primarily discussed in anecdotal reports. The landscape includes clinical evidence and community experiences.
The big picture
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, affecting millions worldwide. While traditional antiepileptic drugs (AEDs) remain the cornerstone of treatment, there is growing interest in alternative therapeutic approaches, including peptides. Peptides are short chains of amino acids that can influence various biological processes, and their potential role in epilepsy is being explored both in clinical settings and among biohackers. This article aims to delineate the peptides most discussed regarding epilepsy, categorizing them into those with FDA-approved indications, those in active clinical trials, and those primarily used anecdotally. For broader context, see the broader research library and our peptide stacking guide.
What the clinical evidence shows
Among the peptides studied for epilepsy, ACTH (Acthar Gel) stands out as an FDA-approved treatment specifically for infantile spasms, a severe form of epilepsy in infants. ACTH is known to exert its effects by acting on the adrenal cortex, leading to increased cortisol production, which has been shown to help control seizures in this population. Controlled clinical trials have demonstrated its efficacy in reducing seizure frequency in patients with infantile spasms.
Other peptides, such as Selank and GHRP-6, are being studied for their neuroprotective and neuroregenerative properties. However, these peptides are not FDA-approved for any indication in the United States. Research is ongoing to explore their potential mechanisms and effects on seizure activity, but as of now, there are no conclusive clinical trial results that support their use in epilepsy management.
What the community reports anecdotally
Anecdotal reports from community forums and biohacker circles often highlight the use of peptides like Selank and GHRP-6 for managing epilepsy symptoms. Users report varying experiences, suggesting improvements in seizure control or a reduction in anxiety associated with seizures. However, it is crucial to note that these claims are entirely anecdotal and lack the rigorous validation of controlled clinical trials. No systematic studies confirm the effectiveness of these peptides for epilepsy, and reliance on self-reported benefits can be misleading.
Key points at a glance
- ACTH (Acthar Gel) is FDA-approved for treating infantile spasms.
- Selank and GHRP-6 are discussed in anecdotal reports but lack FDA approval for epilepsy.
- Controlled clinical trials support ACTH's efficacy in reducing seizure frequency in infants.
- Anecdotal community reports should not be considered clinical evidence.
- Research is ongoing for various peptides, but results are not yet conclusive.
Safety and what to watch for
While ACTH is an established treatment, it is not without risks. Potential side effects include hypertension, weight gain, and increased susceptibility to infections due to immune suppression. The use of non-FDA-approved peptides, such as Selank and GHRP-6, poses additional risks, as their safety profiles are not well understood. Off-label or unregulated use can lead to unexpected adverse effects, and it is essential to approach such treatments with caution.
Open questions
Significant gaps remain in our understanding of the role peptides may play in epilepsy management. Future research is necessary to explore the mechanisms of action, optimal dosing, and long-term safety of various peptides. Regulatory uncertainty also surrounds many of these compounds, limiting their availability for clinical use in the United States. Ongoing studies may provide clearer insights into their potential therapeutic benefits.
Bottom line
While peptides like ACTH have established roles in treating specific forms of epilepsy, many others are still under investigation or used anecdotally. Caution is advised when considering peptides outside of established clinical guidelines.
This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Epilepsy or any indication. Do not start or change therapy without consulting a qualified clinician.